| Michael S Bagan, MD | |
|
5435 Feltl Rd, Minnetonka, MN 55343-7983 | |
| (952) 835-9880 | |
| (952) 857-1554 |
| Full Name | Michael S Bagan |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 13 Years |
| Location | 5435 Feltl Rd, Minnetonka, Minnesota |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255628806 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 4301098923 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Park Nicollet Methodist Hospital | Saint louis park, MN | Hospital |
| North Memorial Health | Robbinsdale, MN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Emergency Physicians Professional Association | 9537072657 | 205 |
News Archive
American Medical Systems a leading provider of world-class devices and therapies for male and female pelvic health, announced today the signing of a research grant contract for six sites to evaluate anatomical, functional and safety outcomes of two different treatments for vaginal prolapse, Anterior Colporrhaphy, a technique which uses traditional suture plication, versus the Elevate Anterior and Apical Prolapse Repair System.
International biotechnology firm Cytonet recently launched the first ever clinical trial in the United States using an investigational liver cell infusion to treat urea cycle disorders (UCD) in children. The first patient in the Phase II trial, which will seek to enroll 20 patients in 12 medical centers, is a child with citrullinemia, which is a hereditary UCD. He received six liver cell infusions on six consecutive days at Yale School of Medicine in New Haven, Conn.
The goal for many cancer patients is to reach the five-year, disease-free mark, but new research from UR Medicine's Wilmot Cancer Institute suggests that two years might be a more practical survival goal for people with follicular lymphoma.
Investigators at St. Jude Children's Research Hospital have demonstrated in laboratory studies a new treatment for the pediatric eye cancer retinoblastoma that appears to be more effective than the current standard therapy, and more likely to prevent the recurrence of this cancer. A report on their work appears in the October 15 issue of Clinical Cancer Research.
› Verified 5 days ago
| Entity Name | Emergency Physicians Professional Association |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1801871934 PECOS PAC ID: 9537072657 Enrollment ID: O20031106000068 |
News Archive
American Medical Systems a leading provider of world-class devices and therapies for male and female pelvic health, announced today the signing of a research grant contract for six sites to evaluate anatomical, functional and safety outcomes of two different treatments for vaginal prolapse, Anterior Colporrhaphy, a technique which uses traditional suture plication, versus the Elevate Anterior and Apical Prolapse Repair System.
International biotechnology firm Cytonet recently launched the first ever clinical trial in the United States using an investigational liver cell infusion to treat urea cycle disorders (UCD) in children. The first patient in the Phase II trial, which will seek to enroll 20 patients in 12 medical centers, is a child with citrullinemia, which is a hereditary UCD. He received six liver cell infusions on six consecutive days at Yale School of Medicine in New Haven, Conn.
The goal for many cancer patients is to reach the five-year, disease-free mark, but new research from UR Medicine's Wilmot Cancer Institute suggests that two years might be a more practical survival goal for people with follicular lymphoma.
Investigators at St. Jude Children's Research Hospital have demonstrated in laboratory studies a new treatment for the pediatric eye cancer retinoblastoma that appears to be more effective than the current standard therapy, and more likely to prevent the recurrence of this cancer. A report on their work appears in the October 15 issue of Clinical Cancer Research.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael S Bagan, MD 5435 Feltl Rd, Minnetonka, MN 55343-7983 Ph: (952) 835-9880 | Michael S Bagan, MD 5435 Feltl Rd, Minnetonka, MN 55343-7983 Ph: (952) 835-9880 |
News Archive
American Medical Systems a leading provider of world-class devices and therapies for male and female pelvic health, announced today the signing of a research grant contract for six sites to evaluate anatomical, functional and safety outcomes of two different treatments for vaginal prolapse, Anterior Colporrhaphy, a technique which uses traditional suture plication, versus the Elevate Anterior and Apical Prolapse Repair System.
International biotechnology firm Cytonet recently launched the first ever clinical trial in the United States using an investigational liver cell infusion to treat urea cycle disorders (UCD) in children. The first patient in the Phase II trial, which will seek to enroll 20 patients in 12 medical centers, is a child with citrullinemia, which is a hereditary UCD. He received six liver cell infusions on six consecutive days at Yale School of Medicine in New Haven, Conn.
The goal for many cancer patients is to reach the five-year, disease-free mark, but new research from UR Medicine's Wilmot Cancer Institute suggests that two years might be a more practical survival goal for people with follicular lymphoma.
Investigators at St. Jude Children's Research Hospital have demonstrated in laboratory studies a new treatment for the pediatric eye cancer retinoblastoma that appears to be more effective than the current standard therapy, and more likely to prevent the recurrence of this cancer. A report on their work appears in the October 15 issue of Clinical Cancer Research.
› Verified 5 days ago
Dr. Kendal Farrar, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 5435 Feltl Rd, Minnetonka, MN 55343 Phone: 952-835-9880 Fax: 952-857-1554 | |
Taj Melson, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 5435 Feltl Rd, Minnetonka, MN 55343 Phone: 952-835-9880 Fax: 952-857-1554 | |
Edgar Austria, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 5435 Feltl Rd, Minnetonka, MN 55343 Phone: 952-857-1154 Fax: 952-857-1154 | |
Justin Matthew Steinberg, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 5435 Feltl Rd, Minnetonka, MN 55343 Phone: 952-835-9880 Fax: 952-857-1554 | |
Arthur James Puff, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 15008 Crown Dr, Minnetonka, MN 55345 Phone: 952-933-9735 | |
Dr. Robert Anderson, D.O. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 5435 Feltl Rd, Minnetonka, MN 55343 Phone: 952-835-9880 | |
Dr. Michael Steven Schwemm, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 5435 Feltl Rd, C/o Eppa, Minnetonka, MN 55343 Phone: 952-835-9880 |